{"entity":{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","aka":["CERTIS1"],"tldr":"A phase 1/2 trial of Palacaparib, Temozolomide, Trastuzumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.","summary":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies. ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 695 participants. Primary completion is estimated at 2028-02-07. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd). Registered primary measures: Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs); Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs; Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05417594","url":"https://clinicaltrials.gov/study/NCT05417594"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["palacaparib","temozolomide","trastuzumab","trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 695 participants. Primary completion is estimated at 2028-02-07. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05417594","phase":"1/2","setting":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","sponsor":"AstraZeneca","participation":[{"nct":"NCT05417594","source":"https://clinicaltrials.gov/study/NCT05417594","fetchedAt":"2026-10-07T16:53:41.920Z","studySha256":"91d5930749b792d57fffad177e31747841622e18be9d250a314970c450fcdd0b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-05","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":695,"enrolmentType":"ESTIMATED","siteCount":32,"recruitingSiteCount":25,"countries":["Australia","Germany","South Korea","Spain","Sweden","United Kingdom","United States"]}],"started":"2022-06-24","startedType":"actual","enrolled":695,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05417594/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}